The Illucidx COVID-19 DX Solutions

We are preparing to launch several COVID-19 diagnostic solutions. Our diagnostics share a few common traits. 

  • They use isothermal and do not require temperature cycling

  • Simpler and faster than qPCR and give a quick yes/no answer as an effective screening tool

  • Does not utilize qPCR reagents and therefore, does not cannibalize reagants form other tests 

  • Not subject to the same reagent shortages as qPCR during the pandemic

  • Can work without a formal extraction method

  • Uses our patented primer design strategy for pathogen detection

High Throughput Laboratory Diagnostics for COVID-19

Illucidx COVID-19 Dx RT-LAMP is a reverse transcription (RT), isothermal, loop-mediated amplification (LAMP) nucleic acid amplification test (NAAT) intended for the qualitative detection of SARS-CoV-2 genetic material (RNA) in nasopharyngeal (NP) swabs from individuals with signs and symptoms of COVID-19 infection. The Illucidx COVID-19 Dx RT-LAMP is intended for use by trained clinical laboratory personnel specifically instructed and trained molecular techniques of RT-LAMP, nucleic acid extraction, and in vitro diagnostic procedures.


Our COVID-19 diagnostic reagent that can utilize equipment commonly found in diagnostic laboratories is ready for deployment as a key component of a Laboratory Developed Test (LDT). We are clinically validating and seeking Health Canada and FDA emergency use authorization. If interested, we can provide the primers, reagents, and consulting to get your laboratory rapidly running loop-mediated amplification to detect COVID-19 without having to navigate the current qPCR reagent shortages created by the global pandemic. Clinical validation data demonstrates that the level of detection using our primer sets approaches that of currently deployed qPCR based tests.

Please see the Instruction For Use (IFU) document for further details and validation data. This diagnostic has been clinically validated and Health Canada and FDA's independent review of this validation is pending. 



For support, more details, or requests please contact us now: 

The Illucidx COVID-19 DX

Near-Patient Solutions

Illucidx is accelerating the development of our point-of-care diagnostic platform and has joined with industry partners to bring to market a COVID-19 point-of-care test.

We will provide a diagnostic tool that can be taken to remote clinics, be used by EMS at the location of the patient, and can be deployed at ports of entry for screening.  

Check back here soon or contact us directly for updates on this product.


Headquartered in Calgary, Alberta, Canada we hope to enable broad access to ultra-sensitive diagnostics tools for settings across the globe. Our first priority is, and will always remain, to improve clinical outcomes.

Please email for direct number


3655 36 St NW 

Calgary, AB T2L 1Y8


  • LinkedIn

© 2020 Illucidx Inc Previously Elucidx Inc.